BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

...In mice with alcoholic steatosis, hepatocyte-specific SLC7A11 knockout or treatment with the SLC7A11 inhibitor Azulfidine sulfasalazine...
...or administration of an mGluR5 inhibitor tool compound decreased hepatic fat accumulation. Pfizer Inc. markets Azulfidine...
BioCentury | Apr 13, 2017
Distillery Therapeutics

Cancer

...apoptosis compared with SLC7A11 knockdown or APR-247 alone. In one of the cell lines, Azulfidine sulfasalazine...
...strategy alone, and in the xenograft model, the combination increased survival. Also in the models, Azulfidine...
...Phase I testing to treat esophageal cancer and myelodysplastic syndrome (MDS). Pfizer Inc. markets Azulfidine sulfasalazine...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

...breast cancer cells, inhibition of the glutamine-dependent xCT by small interfering RNA knockdown or Azulfidine sulfasalazine...
...stress compared with no inhibition. In glutamine-dependent breast cancer cells and in mouse xenograft models, sulfasalazine...
...Next steps could include developing improved xCT inhibitors derived from sulfasalazine. Pfizer Inc. markets Azulfidine sulfasalazine...
BioCentury | Jul 1, 2013
Strategy

RAtcheting back

...whether the next step was to add generic sulfasalazine and hydroxychloroquine or to add Enbrel. Sulfasalazine...
...The monthly price tag for the generic combination is $154.08 - 95% less than Enbrel. Sulfasalazine...
BioCentury | Jun 17, 2013
Clinical News

Enbrel etanercept: Data

...mg Enbrel as an add-on to methotrexate was non-inferior to initial therapy with the generics sulfasalazine...
...mg Enbrel as an add-on to methotrexate was non-inferior to initial therapy with the generics sulfasalazine...
BioCentury | Jun 13, 2013
Clinical News

VA researchers recommend delaying use of Enbrel for RA

...once-weekly Enbrel as an add-on to methotrexate was non-inferior to initial therapy with the generics sulfasalazine...
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Cancer

...11 cysteine glutamate transporter (SLC7A11; xCT) In vitro and mouse studies suggest the xCT inhibitor sulfasalazine...
...sulfasalazine and chemotherapy increased CLL apoptosis compared with chemotherapy alone. In mouse models of CLL, sulfasalazine...
...therapies that block stromal cell protection of CLL cells in vitro and in animals. Generic sulfasalazine...
BioCentury | Sep 22, 2011
Distillery Therapeutics

Indication: Neurology

...7 member 11 cysteine glutamate transporter (SLC7A11; xCT) Mouse studies suggest the xCT blocker Azulfidine sulfasalazine...
...mice implanted with human gliomas, glutamate release from tumor cells triggered epileptic events. Animals receiving Azulfidine...
...untreated controls. Next steps could include testing Azulfidine in additional mouse models. Pfizer Inc. markets Azulfidine...
BioCentury | Aug 31, 2009
Clinical News

PMI-001: Phase IIb data

...daily met the primary endpoint of an ACR20 response at 6 months compared with 1g sulfasalazine...
...had significantly higher ACR50 rates (54.1% vs. 4%) and ACR70 rates (37.8% vs. 4%) vs. sulfasalazine...
BioCentury | Jun 29, 2009
Clinical News

Enbrel etanercept: Phase IV data

...ASAS 20 (75.9% vs. 52.9%) at week 16 compared with patients who received 3 g/day sulfasalazine...
...more patients in the Enbrel arm were in partial remission at week 16 compared with sulfasalazine...
Items per page:
1 - 10 of 25